ArticleMethods in molecular biology (Clifton, N.J.)2025
Development of ELISA Assay for Antibody Detection in Cancer Vaccine Research.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of Trilysine-Cross-Linked Gellan Gum for Intratumoral Delivery of Anti-PD-1 in a Colorectal Cancer Mouse Tumor Model.ACS biomaterials science & engineering · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer vaccines represent a promising strategy in tumor immunotherapy, aiming to elicit robust immune responses against tumor-specific antigens. The accurate measurement of antibody responses is critical in evaluating vaccine efficacy. Enzyme-linked immunosorbent assay (ELISA) offers a reliable, sensitive, and specific method for this purpose. This chapter discusses the development and optimization of ELISA for detecting total and antigen-specific antibodies in cancer vaccine research. Key considerations include customization of ELISA protocols, optimization of assay parameters, and selection of appropriate buffer systems, substrates, and controls. By standardizing these elements, researchers can achieve consistent and reproducible results, advancing the field of cancer immunotherapy and enhancing our understanding of immune mechanisms in oncology.
Indexed as
Identifiers
40266527What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.